SCHEMBL16258192

SCHEMBL16258192

NC(=O)CNC(=O)CNC(=O)OCc1ccccc1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.58
PRSS1 P07477 2/20 0.57
TPSAB1 Q15661 2/20 0.57
TPSD1 Q9BZJ3 1/20 0.57
TPSG1 Q9NRR2 1/20 0.57
LMNA P02545 2/20 0.55
SMN1; SMN2 Q16637 1/20 0.55
KDM1A O60341 1/20 0.53
RCOR1 Q9UKL0 1/20 0.53
HTT P42858 2/20 0.52
PLAU P00749 1/20 0.52
MAPK1 P28482 1/20 0.52
CA12 O43570 2/20 0.50
CA1 P00915 2/20 0.50
CA2 P00918 2/20 0.50
CA9 Q16790 2/20 0.50
NPSR1 Q6W5P4 1/20 0.50
CTSL P07711 1/20 0.50
CTSB P07858 1/20 0.50
CTSS P25774 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8156969 1.00 ALDH1A1 (0.58) ALDH1A1PRSS1TPSAB1TPSD1TPSG1
SCHEMBL5485588 0.94 LMNA (0.61) ALDH1A1PRSS1TPSAB1TPSD1TPSG1
SCHEMBL2820683 0.94 LMNA (0.61) ALDH1A1PRSS1TPSAB1TPSD1TPSG1
Acetic Acid SCHEMBL8324881 0.89 LMNA (0.56) ALDH1A1LMNASMN1; SMN2HTTPLAU
SCHEMBL11126514 0.88 ALDH1A1 (0.58) ALDH1A1PRSS1TPSAB1TPSD1TPSG1
SCHEMBL30440860 0.88 ALDH1A1 (0.60) ALDH1A1PRSS1TPSAB1TPSD1TPSG1
SCHEMBL5873775 0.88 ALDH1A1 (0.60) ALDH1A1PRSS1TPSAB1TPSD1TPSG1
SCHEMBL8178335 0.88 ALDH1A1 (0.60) ALDH1A1PRSS1TPSAB1TPSD1TPSG1
SCHEMBL8327761 0.86 ALDH1A1 (0.59) ALDH1A1PRSS1TPSAB1TPSD1TPSG1
SCHEMBL30576720 0.86 PRSS1 (0.71) ALDH1A1PRSS1TPSAB1TPSD1TPSG1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2805732-B1 Polymer-drug conjugates for the treatment of amyloidosis FUNDACIÓN COMUNIDAD VALENCIANA CT DE INVESTIGACIÓN PRINCIPE FELIPE (ES) 2016-09-28 EP disclosed
US-20160114055-A1 POLYMER DRUG CONJUGATES FOR THE TREATMENT OF AMYLOIDOSIS FUNDACION DE LA COMUNIDAD VALENCIANA "CENTRO DE INVESTIGACIONES PRINCIPE FELIPE" (ES) 2016-04-28 US disclosed
EP-2805732-A1 Polymer-drug conjugates for the treatment of amyloidosis Fundación Comunidad Valenciana Centro de Investigación Principe Felipe (ES) 2014-11-26 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160114055-A1 POLYMER DRUG CONJUGATES FOR THE TREATMENT OF AMYLOIDOSIS FAP, MAPT, TTR ALDH1A1 2105/4885PRSS1 3015/4885TPSAB1 2619/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.